Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs

被引:31
|
作者
Winograd, Rachel P. [1 ]
Wood, Claire A. [1 ]
Stringfellow, Erin J. [1 ]
Presnall, Ned [2 ]
Duello, Alex [1 ]
Horn, Phil [1 ]
Rudder, Tim [3 ]
机构
[1] Univ Missouri St Louis, Missouri Inst Mental Hlth, 4633 World Pkwy Circle Dr, St Louis, MO 63134 USA
[2] Washington Univ, Dept Psychiat, 1 Brookings Dr, St Louis, MO 63130 USA
[3] Missouri Dept Mental Hlth, 1706 East Elm St, Jefferson City, MO 65101 USA
关键词
Opioid use disorder; Buprenorphine; Substance use treatment; State targeted response; LONG-TERM OUTCOMES; ASSISTED TREATMENT; BUPRENORPHINE TREATMENT; MAINTENANCE THERAPY; COUNSELOR ATTITUDES; UNITED-STATES; CARE; DEPENDENCE; BARRIERS; DISCONTINUATION;
D O I
10.1016/j.jsat.2019.06.015
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Leaders of Missouri's State Targeted Response to the opioid crisis (STR) grant have prioritized increasing access to treatment medications for opioid use disorder (MOUD) through a "Medication First" approach. This conceptual framework prioritizes rapid, sustained, low-barrier access to MOUD for optimal impact on decreased illicit drug use and mortality. Medication First principles and practices were facilitated through state-level structural changes and disseminated to participating community treatment programs via a multi-pronged, multi-disciplinary approach. In the first nine months of STR, 14 state-contracted treatment agencies operating 38 sites used STR funding to implement the Medication First model. Methods: We utilized state billing and service data to make comparisons before and during STR on the following outcomes: MOUD utilization, timely access to MOUD, amount of psychosocial services delivered, treatment retention at 1, 3, and 6 months, and monthly price of treatment. We conducted follow-up analyses examining differences across MOUD types (no medication, methadone, buprenorphine, oral naltrexone, mixed antagonist + agonist, and extended release naltrexone). Results: During STR, MOUD utilization increased (44.8% to 85.3%), timeliness of MOUD receipt improved (Median of 8 days vs. 0 days), there were fewer psychosocial services delivered, treatment retention improved at one, three, and six month timeframes, and the median cost per month was 21% lower than in the year prior to STR. All differences were driven by increased utilization of buprenorphine. Conclusions: Findings suggest Medication First implementation through STR was successful in all targeted domains. Though much more work is needed to further reduce logistical, financial, and cultural barriers to improved access to maintenance MOUD, the steps taken through Missouri's STR grant show significant promise at making swift and drastic transformations to a system of care in response to a growing public health emergency.
引用
收藏
页码:55 / 64
页数:10
相关论文
共 50 条
  • [31] Hearing Aid Use and Adherence to Treatment in a Publicly-Funded Health Service from the City of Sao Paulo, Brazil
    Iwahashi, Juliana Harumi
    Jardim, Isabela de Souza
    Shirayama, Yoshihisa
    Yuasa, Motoyuki
    Bento, Ricardo Ferreira
    INTERNATIONAL ARCHIVES OF OTORHINOLARYNGOLOGY, 2015, 19 (03) : 210 - 215
  • [32] EXPERIENCES OF MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER AMONG WOMEN IN RECOVERY PROGRAMS
    Kedia, Satish K.
    Schmidt, Michael
    Dillon, Patrick J.
    Ahuja, Nikhil A.
    ANNALS OF BEHAVIORAL MEDICINE, 2021, 55 : S208 - S208
  • [33] Prehospital Use of Medication-Assisted Treatment for Opioid Use Disorder: A Rapid Review of Implementation Approaches and Outcomes
    Denton, Edward E.
    Ventura, Christian Angelo, I
    SUBSTANCE ABUSE AND REHABILITATION, 2025, 16 : 55 - 69
  • [34] Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016
    Askari, Melanie S.
    Martins, Silvia S.
    Mauro, Pia M.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 114
  • [35] Association of Medication Treatment for Opioid Use Disorder With Suicide Mortality
    Watts, Bradley, V
    Gottlieb, Daniel J.
    Riblet, Natalie B.
    Gui, Jiang
    Shiner, Brian
    AMERICAN JOURNAL OF PSYCHIATRY, 2022, 179 (04): : 298 - 304
  • [36] Medication-Based Treatment to Address Opioid Use Disorder
    Leshner, Alan I.
    Dzau, Victor J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (21): : 2071 - 2072
  • [37] Medication-Assisted Treatment for Opioid-Use Disorder
    Oesterle, Tyler S.
    Thusius, Nuna J.
    Rummans, Teresa A.
    Gold, Mark S.
    MAYO CLINIC PROCEEDINGS, 2019, 94 (10) : 2072 - 2086
  • [38] Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis
    Rogal, Shari
    Youk, Ada
    Agbalajobi, Olufunso
    Zhang, Hongwei
    Gellad, Walid
    Fine, Michael J.
    Belperio, Pamela
    Morgan, Timothy
    Good, Chester B.
    Kraemer, Kevin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (07): : 1406 - 1413
  • [39] Medication Treatment of Adolescent Opioid Use Disorder in Primary Care
    Carney, Brittany L.
    Hadland, Scott E.
    Bagley, Sarah M.
    PEDIATRICS IN REVIEW, 2018, 39 (01) : 43 - 45
  • [40] Review of medication-assisted treatment for opioid use disorder
    Ghanem, Nessreen
    Dromgoole, Devin
    Hussein, Ahmad
    Jermyn, Richard T.
    JOURNAL OF OSTEOPATHIC MEDICINE, 2022, 122 (07): : 367 - 374